Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
June 01 2021 - 9:00AM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision
oncology company developing next-generation therapies that target
genetic drivers of cancer, today announced that President and CEO
Athena Countouriotis, M.D., will participate in a
question-and-answer session at the 42nd annual Goldman Sachs
Healthcare Conference on June 9.
Dr. Countouriotis’ session is scheduled to begin at
1:20 p.m. ET and will be accessible via audio webcast through the
Investors page of www.tptherapeutics.com.
About Turning Point Therapeutics
Inc.Turning Point Therapeutics is a clinical-stage
precision oncology company with a pipeline of internally discovered
investigational drugs designed to address key limitations of
existing cancer therapies. The company’s lead drug candidate,
repotrectinib, is a next-generation kinase inhibitor targeting the
ROS1 and TRK oncogenic drivers of non-small cell lung cancer and
advanced solid tumors. Repotrectinib, which is being studied in a
registrational Phase 2 study in adults and a Phase 1/2 study in
pediatric patients, has shown antitumor activity and durable
responses among kinase inhibitor treatment-naïve and pre-treated
patients. The company’s pipeline of drug candidates also includes
TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a
Phase 1 trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; and TPX-0131, a next-generation ALK inhibitor, which is
being studied in a Phase 1/2 trial of previously treated patients
with ALK-positive advanced or metastatic non-small cell lung
cancer. Turning Point’s next-generation kinase inhibitors are
designed to bind to their targets with greater precision and
affinity than existing therapies, with a novel, compact structure
that has demonstrated an ability to potentially overcome treatment
resistance common with other kinase inhibitors. The company is
driven to develop therapies that mark a turning point for patients
in their cancer treatment. For more information, visit
www.tptherapeutics.com.
Forward Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as “plans”, “will”, “believes,”
“anticipates,” “expects,” “intends,” “goal,” “potential” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Turning
Point Therapeutics’ current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Turning Point Therapeutics’ business
in general, risks and uncertainties related to the impact of the
COVID-19 pandemic to Turning Point’s business and the other risks
described in Turning Point Therapeutics’ filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Turning Point
Therapeutics undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contact:Jim
Mazzolajim.mazzola@tptherapeutics.com858-342-8272
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024